FDA accepts NDA for zonisamide oral suspension to treat partial seizures. -Eton Pharma

Eton Pharmaceuticals, Inc., has announced the FDA has accepted for filing the company’s new drug application (NDA) for ET 104 ( zonisamide oral suspension). The application has been assigned a Prescription Drug User Fee Act (PDUFA) date of May 29, 2021. The application was submitted for the treatment of partial seizures in patients with epilepsy. Zonisamide is one of Eton’s three neurology-focused oral liquid product candidates that have been submitted to the FDA, and all three product candidates are expected to be approved and launched in 2021.